Pharmacodynamics of ticlopidine: Relation between dose and time of administration to platelet inhibition

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 8, 1996, Pages 357-361

  Kuzniar, J ^a   Splawinska, B ^a   Malinga, K ^b   Mazurek, A P ^b   Splawinski, J ^b,c  

^a Voivodship Hospital No 2   (Poland)

^b Institute of Drugs   (Poland)

^c Institute of Drugs   (Poland)

Author keywords

Pharmacodynamics; Platelet aggregation; Ticlopidine

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; TICLOPIDINE;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SEX FACTORS; TICLOPIDINE;

EID: 0029782279     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Beving H, Eksborg S, Malmgren RS, Nordlander R, Ryden L, Olsson P 1994 Inter-individual variations of the effect of low dose aspirin regime on platelet cyclooxygenase activity. Thromb Res 74: 39-51
2. Desager JP 1994 Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 26: 347355
3. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M 1985 Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 75: 328-338
4. Feliste R, Delebassee D, Simon MF, Chap H, Defreyn G, Vallee E, Douste-Blazy L, Maffrand JP 1987 Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res 48: 403-415
5. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG, the CATS group 1988 The Canadian American Ticlopidine Study (CATS) on thromboembolic stroke: design, organisation, and baseline results. Stroke 19: 1203-1210
6. Grotta JC, Norris JW, Kamm B and the TASS Baseline and Angiographic Data Subgroup 1992 Prevention of stroke with ticlopidine: who benefits most? Neurology 42: 111-115
7. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B for the Ticlopidine Aspirin Stroke Study Group 1989 A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321: 501-507
8. Patrignani P, Filabozzi P, Patrono C 1982 Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69: 1366-1372
9. Schror K 1993 The basic pharmacology of ticlopidine and clopidogrel. Platelets 4: 252-261
10. 2 in whole blood measured by platelet counter. Thomb Res 34: 93-102
11. Thebault JJ, Blatrix CE, Blanchard JF, Panak EA 1975 Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 18: 485-490
12. Thebault JJ, Blatrix CE, Blanchard JF, Panak EA 1977 The interactions of ticlopidine and aspirin in normal subjects. J Int Med Res 5: 405-411